TDO2 and prostate carcinoma: We evaluated the TCGA and GTEx datasets and reported that TDO2 mRNA levels were considerably higher in prostate cancer tissues than in normal control tissues (Fig. 3a) and increased with prostate cancer development and Gleason score (Fig. 3b).